Share on LinkedInShare on LinkedIn

ARTICLE · 17 JULY 2026

Federal Circuit Decision: When A Typo Costs A Patent Its Priority Date

Wiggin and Dana LLP
Wiggin and Dana LLP
Contributor
Wiggin and Dana LLP

Wiggin and Dana LLP

Wiggin and Dana is a full-service law firm of highly talented, creative and experienced lawyers...

View firm profile
Explore more from Wiggin and Dana LLP

A small drafting mistake can have major consequences in patent law. That was the lesson from Enanta Pharmaceuticals, Inc. v. Pfizer Inc., where the Federal Circuit held in a precedential opinion that Enanta’s patent...

United StatesIntellectual Property
Thomas Landman
Thomas Landman

A small drafting mistake can have major consequences in patent law. That was the lesson from Enanta Pharmaceuticals, Inc. v. Pfizer Inc., where the Federal Circuit held in a precedential opinion that Enanta’s patent could not rely on the filing date of its earlier provisional application. Because the provisional application, as specifically written, did not clearly describe the version of the invention later claimed in the issued patent, Pfizer’s intervening public disclosure of nirmatrelvir—the active ingredient in Paxlovid—constituted prior art that anticipated and invalidated Enanta’s claims.

The issue turned on a single carbon atom! Enanta’s provisional application described a chemical substituent as having a C2-C12 alkyl group, meaning a chain of two to twelve carbon atoms. But the later-issued patent claimed a C1-C12 alkyl group. This was an attempt to cover a one-carbon chain. That one-carbon version was critical for Enanta because it would encompass Pfizer’s nirmatrelvir.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from